Exelon® patch: A better treatment?
Metadata[+] Show full item record
The Exelon patch (transdermal rivastigmine) is the first acetylcholinesterase inhibitor transdermal formulation available to treat mild to moderate Alzheimer's disease (AD), as well as mild to moderate Parkinson's disease dementia (PDD). Rivastigmine may provide greater benefits than other acetylcholinesterase inhibitors in both activities of daily living and global functioning, and is the only medication approved by the US Food and Drug Administration (FDA) to treat PDD. While Exelon is slightly more expensive than other drugs in its class, the transdermal formulation is well tolerated and is preferred by caregivers for its ease of use and ease in keeping drug administration on schedule.
Evidence Based Practice 12(1): 09-10.